Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Stevenson

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Oncology (Williston Park, N.Y.)|December 1, 2000
Irinotecan and UFT/leucovorin in patients with advanced cancersJ P Stevenson, M Redlinger, W Sun, et al.
Seminars in Oncology|March 29, 2001
Follow-up of stage B and C colorectal cancer in the United States and FranceP J O'Dwyer, J P Stevenson, D G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinomaT J Robnett, M Machtay, J P Stevenson, et al.
British Journal of Cancer|June 24, 2004
Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 daysJ H Bilenker, J P Stevenson, M L Gallagher, et al.
Cancer Chemotherapy and Pharmacology|August 24, 1999
Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day scheduleJ P Stevenson, D DeMaria, D Reilly, et al.
Cancer|July 24, 2001
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumorsW Sun, J P Stevenson, M Gallagher, et al.
British Journal of Cancer|February 24, 2005
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cellsD Roberts, J Schick, S Conway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)P J O'Dwyer, J P Stevenson, M Gallagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancerJ P Stevenson, M Redlinger, L A Kluijtmans, et al.
Controlled Clinical Trials|June 1, 1987
An example of expert systems applied to clinical trials: analysis of serial graded exercise ECG test dataJ M Long, J R Slagle, A S Leon, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Oncology (Williston Park, N.Y.)|December 1, 2000
Irinotecan and UFT/leucovorin in patients with advanced cancersJ P Stevenson, M Redlinger, W Sun, et al.
Seminars in Oncology|March 29, 2001
Follow-up of stage B and C colorectal cancer in the United States and FranceP J O'Dwyer, J P Stevenson, D G Haller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinomaT J Robnett, M Machtay, J P Stevenson, et al.
British Journal of Cancer|June 24, 2004
Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 daysJ H Bilenker, J P Stevenson, M L Gallagher, et al.
Cancer Chemotherapy and Pharmacology|August 24, 1999
Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day scheduleJ P Stevenson, D DeMaria, D Reilly, et al.
Cancer|July 24, 2001
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumorsW Sun, J P Stevenson, M Gallagher, et al.
British Journal of Cancer|February 24, 2005
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cellsD Roberts, J Schick, S Conway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)P J O'Dwyer, J P Stevenson, M Gallagher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2001
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancerJ P Stevenson, M Redlinger, L A Kluijtmans, et al.
Controlled Clinical Trials|June 1, 1987
An example of expert systems applied to clinical trials: analysis of serial graded exercise ECG test dataJ M Long, J R Slagle, A S Leon, et al.
Pageof 3